Nuwellis, Inc. (NUWE) Financial Ratios
22 years of historical data (2004–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.89
↓-70% vs avg
5yr avg: 9.59
30Y Low1.0·High47.9
ROE
↓
-382.7%
↑-84% vs avg
5yr avg: -208.0%
30Y Low-457%·High-63%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NUWE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Nuwellis, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $12M | $62M | $48M | $78M | $328M | $781M | $44M | $4M | $3M | $3M |
| Enterprise Value | $1M | $11M | $57M | $45M | $62M | $320M | $767M | $43M | $-1480004 | $-12595003 | $2M |
| P/E Ratio → | -0.04 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.22 | 1.45 | 7.08 | 5.41 | 9.17 | 41.40 | 104.96 | 7.98 | 0.80 | 0.84 | 2.33 |
| P/B Ratio | 2.89 | 4.58 | 9.48 | 14.93 | 6.34 | 12.64 | 47.86 | 22.11 | 1.00 | 1.00 | 1.71 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NUWE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.36 | 6.56 | 5.06 | 7.21 | 40.45 | 103.06 | 7.83 | -0.30 | -3.54 | 1.30 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
NUWE Profitability
Margins and return-on-capital ratios measuring operating efficiency
Nuwellis, Inc. earns an operating margin of -134.3%. Operating margins have expanded from -198.9% to -134.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -382.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 62.0% | 62.0% | 66.7% | 56.2% | 55.7% | 56.7% | 54.5% | 51.7% | 26.6% | 22.2% | 44.7% |
| Operating Margin | -134.3% | -134.3% | -125.7% | -198.9% | -201.0% | -246.5% | -228.8% | -328.5% | -340.9% | -416.9% | -1215.1% |
| Net Profit Margin | -211.8% | -211.8% | -127.7% | -228.0% | -170.0% | -246.9% | -212.8% | -328.7% | -340.8% | -376.6% | -1225.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -382.7% | -382.7% | -229.2% | -259.6% | -75.8% | -92.5% | -173.0% | -457.1% | -153.6% | -148.7% | -226.8% |
| ROA | -219.2% | -219.2% | -113.7% | -117.3% | -52.7% | -77.6% | -123.7% | -252.0% | -125.1% | -103.2% | -98.6% |
| ROIC | -433.0% | -433.0% | -766.2% | -7732.5% | -184.2% | -142.2% | -756.1% | -1682.7% | -2325.2% | -2063.0% | -2706.6% |
| ROCE | -213.8% | -213.8% | -158.1% | -132.6% | -72.9% | -89.7% | -182.3% | -442.3% | -152.8% | -144.0% | -151.2% |
NUWE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $1M exceeds total debt of $328000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.08 | 0.24 | 0.08 | 0.05 | 0.02 | 0.22 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.29 | -0.70 | -0.95 | -1.36 | -0.29 | -0.86 | -0.42 | -0.92 | -0.96 | -0.75 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.05 | -1.05 | -1.96 | -5.06 | -1.86 | — | — | — | — | -5.82 | -31.08 |
Net cash position: cash ($1M) exceeds total debt ($328000)
NUWE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.71x means Nuwellis, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 1.08x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 2.59x to 1.71x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.71 | 1.71 | 3.46 | 2.59 | 4.86 | 8.50 | 5.17 | 1.20 | 2.86 | 8.54 | 0.74 |
| Quick Ratio | 1.08 | 1.08 | 2.79 | 1.96 | 4.29 | 7.65 | 4.35 | 0.67 | 2.28 | 7.78 | 0.53 |
| Cash Ratio | 0.36 | 0.36 | 1.99 | 1.20 | 3.90 | 7.32 | 4.03 | 0.38 | 1.93 | 7.46 | 0.41 |
| Asset Turnover | — | 1.35 | 0.89 | 0.91 | 0.35 | 0.26 | 0.37 | 0.98 | 0.57 | 0.19 | 0.17 |
| Inventory Turnover | 1.65 | 1.65 | 1.70 | 1.94 | 1.42 | 1.21 | 1.14 | 1.48 | 2.21 | 1.74 | 1.05 |
| Days Sales Outstanding | — | 65.89 | 72.12 | 80.34 | 60.07 | 34.56 | 44.39 | 52.92 | 57.40 | 55.99 | 79.85 |
NUWE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Nuwellis, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $7M | $1M | $56125 | $4971 | $1957 | $781 | $44 | $4 | $3 | $3 |
Peer Comparison
Compare NUWE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NUWEYou | $2M | -0.0 | — | — | 62.0% | -134.3% | -382.7% | -433.0% | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ANGO | $469M | -13.6 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 ATRC | $1B | -115.8 | 77.7 | 29.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 CNMD | $1B | 25.2 | 10.2 | 7.8 | 52.8% | 10.3% | 4.7% | 5.8% | 4.3 |
 MMSI | $4B | 29.3 | 13.1 | 17.2 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 BDX | $56B | 26.3 | 14.7 | 20.8 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 EW | $48B | 45.2 | 25.4 | 35.7 | 78.1% | 27.0% | 10.5% | 15.5% | 0.4 |
 ABT | $151B | 11.4 | 15.8 | 23.8 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 22 years · Updated daily
See NUWE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NUWE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NUWE vs NVCR
Side-by-side business, growth, and profitability comparison vs NovoCure Limited.
Start ComparisonNUWE — Frequently Asked Questions
Quick answers to the most common questions about buying NUWE stock.
What is Nuwellis, Inc.'s P/E ratio?
Nuwellis, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
What is Nuwellis, Inc.'s ROE?
Nuwellis, Inc.'s return on equity (ROE) is -382.7%. The historical average is -180.3%.
Is NUWE stock overvalued?
Based on historical data, Nuwellis, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Nuwellis, Inc.'s profit margins?
Nuwellis, Inc. has 62.0% gross margin and -134.3% operating margin.